PMID- 15916923
OWN - NLM
STAT- MEDLINE
DCOM- 20051213
LR  - 20110608
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 7
IP  - 5
DP  - 2005 Aug
TI  - Tumour marker levels in patients with chronic heart failure.
PG  - 840-3
AB  - BACKGROUND: Carbohydrate Antigen 125 (CA 125), a marker for ovarian cancer has 
      been reported to increase in relation to the severity of heart failure. 
      OBJECTIVE: To evaluate the serum levels of CA 125 and other tumour markers, in 
      patients with chronic heart failure. METHODS: Blood levels of CA 125 and other 
      tumour markers were determined in 44 heart failure patients (16 males and 28 
      females; age 66.3+/-6.5 years) before and after optimal medical treatment. Levels 
      were also evaluated in 30 healthy volunteers (11 males and 19 females; age 
      65.7+/-9.8 years). The results in the heart failure patients were grouped 
      according to clinical status (New York Heart Association Class). The mean 
      duration of follow-up was 3+/-1.5 months. RESULTS: The mean serum level of CA 125 
      was 81.9+/-91 in the patient group and 7.5+/-4.8 in control group (p<0.001). The 
      mean CA 19-9 level in the patient group (16.8+/-16.6) was significantly higher 
      than in the control group (4.5+/-2.6) (p<0.001). CA 125 levels increased as the 
      New York Heart Association (NYHA) functional class increased (Class I/II: 
      17.7+/-22.4 U/ml; Class III: 99.6+/-92.1 U/ml; Class IV 136.4+/-102.8 U/ml; 
      p<0.05). There were no significant differences in serum CA 125 and other tumour 
      marker levels before and after optimisation of treatment. Significantly higher 
      serum CA 125 levels were found in patients with pericardial effusion (p=0.002) 
      when compared to patients without pericardial effusion. CONCLUSION: Among the 
      tumour markers evaluated, only CA 125 seems to be specifically related to the 
      presence and severity of heart failure and also the presence of pericardial 
      fluid. Therefore, measurements of CA 125 serum levels might be proposed for the 
      serial assessment of heart failure. Whether CA 125 has a specific biological role 
      in heart failure requires further investigation.
FAU - Varol, Ercan
AU  - Varol E
AD  - Department of Cardiology, Isparta State Hospital, Anadolu Mah. ESO (memur) Evleri 
      C Blok No:5, 32200 Isparta, Turkey. adogan35@hotmail.com
FAU - Ozaydin, Mehmet
AU  - Ozaydin M
FAU - Dogan, Abdullah
AU  - Dogan A
FAU - Kosar, Feridun
AU  - Kosar F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (CA-125 Antigen)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Mucin-1)
RN  - 0 (alpha-Fetoproteins)
SB  - IM
MH  - Aged
MH  - CA-125 Antigen/*blood
MH  - CA-19-9 Antigen/blood
MH  - Female
MH  - Heart Failure/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mucin-1/blood
MH  - Prospective Studies
MH  - Ventricular Dysfunction, Left/blood
MH  - alpha-Fetoproteins/analysis
EDAT- 2005/05/27 09:00
MHDA- 2005/12/15 09:00
CRDT- 2005/05/27 09:00
PHST- 2004/07/16 00:00 [received]
PHST- 2004/12/14 00:00 [revised]
PHST- 2004/12/20 00:00 [accepted]
PHST- 2005/05/27 09:00 [pubmed]
PHST- 2005/12/15 09:00 [medline]
PHST- 2005/05/27 09:00 [entrez]
AID - S1388-9842(04)00377-0 [pii]
AID - 10.1016/j.ejheart.2004.12.008 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2005 Aug;7(5):840-3. doi: 10.1016/j.ejheart.2004.12.008.